Showing results (171-180 of 781) with videos related to
Sort By:
Pageof 79
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.Blood Reviews|December 4, 2010
Multiple myeloma: biology of the diseaseAnuj Mahindra, Teru Hideshima, Kenneth C AndersonInternational Journal of Hematology|April 22, 2016
Histone deacetylase inhibitors in multiple myeloma: from bench to bedsideTakeshi Harada, Teru Hideshima, Kenneth C AndersonBMC Biochemistry|November 26, 2008
Targeting the UPS as therapy in multiple myelomaDharminder Chauhan, Giada Bianchi, Kenneth C AndersonBlood Cancer Journal|September 8, 2018
The biological significance of histone modifiers in multiple myeloma: clinical applicationsHiroto Ohguchi, Teru Hideshima, Kenneth C AndersonExpert Review of Precision Medicine and Drug Development|August 20, 2021
Proteomics-inspired precision medicine for treating and understanding multiple myelomaMatthew Ho, Giada Bianchi, Kenneth C AndersonBlood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.Frontiers in Immunology|September 14, 2020
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsChen Zhu, Zhili Song, Anlai Wang, et al.Pageof 79